RHHBY - Why MacroGenics Soared Nearly 9% Higher Today
A notable decliner on Wednesday, MacroGenics (NASDAQ: MGNX) stock came roaring back the next day to close almost 9% higher. The company has suffered a big setback, but there are obviously investors who still believe it has potential to make them money.
The setback is that the company's only Food and Drug Administration (FDA)-approved drug, breast cancer treatment Margenza, didn't perform impressively in a final analysis. In that study, Margenza plus chemotherapy was compared to a prominent cancer treatment, Roche 's (OTC: RHHBY) trastuzumab (branded as Herceptin ), also in combination with chemotherapy.
Image source: Getty Images.
For further details see:
Why MacroGenics Soared Nearly 9% Higher Today